^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tofacitinib

    i
    Other names: CP-690,550, CP-690550, CP690550
    Company:
    Generic mfg.
    Drug class:
    JAK inhibitor
    Related drugs:
    4d
    The efficacy and safety of Tofacitinib combined with mycophenolate mofetil versus tofacitinib in patients with glucocorticoid resistant ICIs-related myocarditis: a multicenter, randomized, controlled clinical study (ChiCTR2500114368)
    P=N/A, N=116, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    |
    tofacitinib
    4d
    A Retrospective Study Comparing Tofacitinib with Antihistamines in the Treatment of Cholinergic Urticaria and Symptomatic Dermographism (ChiCTR2600117340)
    P4, N=20, Not yet recruiting, Dermatology Hospital of Southern Medical University; Dermatology Hospital of Southern Medical University
    New P4 trial
    |
    tofacitinib
    4d
    A Phase II Study of Iparomlimab and Tuvonralimab(PD-1/CTLA-4 Bispecific Antibody)Plus Tofacitinib in Patients With Immunotherapy-Refractory Advanced Esophageal Squamous Cell Carcinoma (ChiCTR2500115509)
    P4, N=26, Not yet recruiting, Shandong Provincial Hospital Affiliated to Shandong First Medical University; Shandong Provincial Hospital Affiliated to Shandong First Medical Univer
    New P4 trial
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604) • tofacitinib
    4d
    A single-center exploratory study on the efficacy and safety of tetrandrine tablets in the treatment of interstitial lung disease associated with rheumatoid arthritis (ChiCTR2500107574)
    P=N/A, N=60, Recruiting, The First Affiliated Hospital of Army Medical University (Southwest Hospital); The First Affiliated Hospital of Army Medical University (Southwest Hos | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Nov 2025
    Enrollment open • Trial initiation date
    |
    Rituxan (rituximab) • cyclophosphamide • prednisone • hydroxychloroquine • tofacitinib • CBT-1 (tetrandrine)
    5d
    Interferon-Type-I Response and Autophagy Independently Regulate Radiation-Induced HLA-Class-I Molecule Expression in Lung Cancer. (PubMed, Curr Issues Mol Biol)
    The effect of RT (8 and 3 × 8 Gy) on Interferon beta (IFNβ), IFN-stimulated genes (ISGs), and HLA-class-I expression in combination with IFN-type-I-response inhibitors (Ruxolitinib, Tofacitinib, Amlexanox) targeting the JAK and TBK1 was studied with Flow cytometry and RT-PCR. The current study supports the theory that baseline autophagy, RT-induced autophagy blockage, and IFN-type-I response enhancement define the HLA-class-I levels in NSCLC cells. This complex interplay emerges as a promising target for the development of radio-vaccination strategies to enhance the efficacy of radio-immunotherapy.
    Journal • IO biomarker
    |
    ATG7 (Autophagy Related 7) • IFNB1 (Interferon Beta 1) • MAP1LC3A (Microtubule Associated Protein 1 Light Chain 3 Alpha)
    |
    Jakafi (ruxolitinib) • Aphthasol (amlexanox) • tofacitinib
    7d
    KRXeljanzJIA: Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Pfizer | N=375 --> 10
    Enrollment change
    |
    tofacitinib
    7d
    Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome (clinicaltrials.gov)
    P=N/A, N=24, Enrolling by invitation, Tongji Hospital | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    tofacitinib
    14d
    Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov)
    P4, N=10, Not yet recruiting, University of California, San Francisco
    New P4 trial
    |
    5-fluorouracil • Jakafi (ruxolitinib) • hydroxychloroquine • cyclosporine • roflumilast • tofacitinib • Cosentyx (secukinumab) • Dupixent (dupilumab) • Ilumya (tildrakizumab-asmn) • chloroquine phosphate
    19d
    TOFAST: Tofacitinib in Adult Patients With Moderate to Severe Ulcerative Colitis (clinicaltrials.gov)
    P=N/A, N=152, Completed, Pfizer | Recruiting --> Completed | N=280 --> 152
    Trial completion • Enrollment change
    |
    tofacitinib
    19d
    The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea (clinicaltrials.gov)
    P=N/A, N=186, Not yet recruiting, The Fourth Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    |
    hydroxychloroquine • tofacitinib
    20d
    Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications (clinicaltrials.gov)
    P1/2, N=20, Enrolling by invitation, National Institute of Allergy and Infectious Diseases (NIAID) | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    Xeljanz XR (tofacitinib XR) • tofacitinib
    26d
    Recent advances in biologic therapies for ankylosing spondylitis: A 2024 update. (PubMed, Allergol Immunopathol (Madr))
    This comprehensive analysis assesses therapeutic outcomes and adverse effects of TNFi, IL17i, and JAKi in AS care.
    Review • Journal
    |
    IL17A (Interleukin 17A)
    |
    tofacitinib • Cosentyx (secukinumab) • Simponi (golimumab)